<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808338</url>
  </required_header>
  <id_info>
    <org_study_id>ST-1517-ALE-MS</org_study_id>
    <nct_id>NCT02808338</nct_id>
  </id_info>
  <brief_title>Servo-Ventilation In-lab PSG Evaluation</brief_title>
  <official_title>Servo-Ventilation In-lab Polysomnography (PSG) Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philips Respironics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philips Respironics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continuous Positive Airway Pressure (CPAP) is the most effective treatment for the
      Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS). CPAP stabilizes the airway and prevents
      instability and collapse. With a stable and patent airway, breathing continues in a normal
      manner, gas exchange is improved, and there is no disruption of sleep related to disturbed
      breathing.

      Auto Servo Ventilation (Auto SV) is a mode of positive airway pressure used to treat
      obstructive and complex central sleep apnea. The main features of the Auto SV mode include:

        -  Normalization of ventilation by automatically adjusting Inspiratory Positive Airway
           Pressure (IPAP) pressure to achieve a target ventilation. IPAP is increased or decreased
           to help stabilize the ventilation.

        -  Provision of timed, back-up breaths during central apneas. The optimal back-up rate is
           automatically determined by the device based on the patient's breathing.

        -  Automatic control of Expiratory Positive Airway Pressure (EPAP) to treat obstructive
           events.

      Several manufacturers produce these types of devices. The algorithms used to determine the
      IPAP, EPAP and minimum respiratory rate are different. The largest number of these devices
      currently in use are the BiPAP AutoSV Advanced System One (Philips Respironics, Murrysville
      PA) and the Variable positive airway pressure (VPAP) Adapt (ResMed Corp., San Diego CA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to better understand the performance and features of the BiPAP autoSV Advanced
      System One. Philips Respironics will evaluate the PolySomnoGraphy (PSG) and Encore data from
      each night. The aim of the study is to characterize the acute outcomes of treatment provided
      by the device and evaluate any modifications made to the Philips Respironics device's
      algorithm

      The participants for this study will be experienced in having used servo ventilation therapy
      at their home because it is only such patients who are already using servo ventilation as
      part of routine clinical care that are eligible for participation.

      Participants will receive four (4) randomized PSG's during which they will receive treatment
      from the following devices in a randomized manner:

        -  FDA released Philips BiPAP AutoSV Advanced System One

        -  A Modified Philips BiPAP ASV

        -  FDA released ResMed S7 VPAP Adapt

        -  FDA released ResMed S9 VPAP Adapt

      The participants sought for this effort will be previously prescribed a servo-ventilation
      device as part of routine clinical care.

      Baseline with PSG

        -  Informed Consent

        -  Inclusion/Exclusion Criteria Review

        -  Demographics

        -  Anthropometric Measurements

        -  PAP Prescription information (if available; from Device or from Medical records). This
           is the pressure settings of the device that was prescribed by the patient's clinical
           sleep medicine provider.

        -  Medical History and physical examination

        -  Sleep History- Including that past 30 day detailed report

        -  Diagnostic PSG history (copies of sleep studies that were performed as part of routine
           clinical care in the past that qualified the patient for the servo-ventilation device)

        -  Current Medications

        -  Vital Signs (at beginning of PSG night)

        -  Research Trial PSG- Randomized to a device Procedures for Each PSG after Baseline

        -  Current Medications

        -  Vital Signs (at beginning of PSG night)

        -  Research Trial PSG- Randomized to one of the four devices (4 research PSGs will be
           performed for each subject).

           30 day Take Home with Modified Philips BiPAP ASV device

      After the last PSG participants will be sent home on Modified Philips Auto Servo Ventilation
      (ASV) study device. A wireless modem with oxygen saturation level (SPO2) connection will be
      connected to the Modified Philips ASV study device. The wireless modem with SPO2 connection
      is for device data collection/transmission purposes only that monitors the usage and
      performance of the device in the home-setting.

        -  The device setting should be set to the following:

             -  P max: 30

             -  EPAP min: 4

             -  Expiratory Positive Airway Pressure maximum (EPAPmax):15

             -  Pressure Support Minimum (PS min): 0

             -  Pressure Support Maximum (PS max): 15

             -  BiFlex (Bi-Level Flex): 2

             -  Rate: Auto

      After 30 day Take Home Participants Will

        -  Return to the Sleep Lab

        -  Complete the end of study questionnaire

        -  Return all of the study equipment

      Additional Take Home with the Modified Philips BiPAP ASV device:

        -  Participants may be asked to use the Modified Philips ASV study device for an additional
           30 days if more data is needed for analysis. Participants will complete the same end of
           day questionnaire noted above.

      After trial completion:

        -  When the Participant is done with the trial they will go back to using their own
           prescribed device.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2015</start_date>
  <completion_date type="Actual">July 6, 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Apnea Hypopnea Index Among Different Polysomnography Devices.</measure>
    <time_frame>4 nights</time_frame>
    <description>The Apnea Hypopnea Index is the number of the apneas and hypopneas during one hour of sleep. The average of these events over one night were compared during each overnight device use.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Sleep Apnea Syndromes</condition>
  <arm_group>
    <arm_group_label>Philips BiPAP AutoSV Advanced System One</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Bi-Level Positive Airway Pressure system will be used and will be configured with these settings.
P max: 30 EPAP min: 4 EPAPmax: 15 Pressure Support (PS) min: 0 Pressure Support (PS) max: 15 BiFlex: 2 Rate: Auto</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified Philips BiPAP ASV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The modified Philips BiPAP ASV will be configured with these settings P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ResMed S7 VPAP Adapt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is an FDA approved device and the following settings will be administered:
End-expiratory Pressure (EEP): 4 PSmin: 3 PSMax: 16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ResMed S9 VPAP Adapt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is an FDA approved device and the following settings will be administered:
EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 20 Max Ramp: Off</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Philips BiPAP AutoSV Advanced System One</intervention_name>
    <description>Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.</description>
    <arm_group_label>Philips BiPAP AutoSV Advanced System One</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Modified Philips BiPAP ASV</intervention_name>
    <description>This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.</description>
    <arm_group_label>Modified Philips BiPAP ASV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ResMed S7 VPAP Adapt</intervention_name>
    <description>This device is FDA approved and will be set to predetermined setting.</description>
    <arm_group_label>ResMed S7 VPAP Adapt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ResMed S9 VPAP Adapt</intervention_name>
    <description>This device is FDA approved and will be set to predetermined setting.</description>
    <arm_group_label>ResMed S9 VPAP Adapt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide consent

          -  Age ≥ 21

          -  Currently prescribed servo ventilation therapy at home

          -  At least two weeks of recent adherence and efficacy data from PAP device demonstrating
             adequate use of therapy (at least 4 hours of use per night and use on at least 9 of 14
             nights)

          -  Current device compliance report demonstrating residual Apnea-Hypopnea Index (AHI) of
             5 or more

        Exclusion Criteria:

          -  Participants who are acutely ill, medically complicated or who are medically unstable

          -  Participants in whom PAP therapy is otherwise medically contraindicated

          -  Participants who are claustrophobic

          -  Symptomatic (&quot;Symptomatic&quot; defined as hospitalized for heart failure or a change in
             cardiac medications, within the last two months) chronic heart failure (NYHA 2-4) and
             reduced LVEF≤45%, AND moderate to severe predominant central sleep apnea

          -  Participants with previously diagnosed respiratory failure or respiratory
             insufficiency and who are known to have elevated arterial carbon dioxide levels while
             awake (PaCO2 ≥ 55mmHg).

          -  Participants requiring any kind of oxygen therapy

          -  Participants who have had surgery of the upper airway, nose, sinus, eyes, or middle
             ear within the previous 90 days

          -  Participants with untreated, non-OSA sleep disorders, including but not limited to;
             insomnia, periodic limb movement syndrome, or restless legs syndrome (PLMI &gt; 10).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sairam Parthasarathy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona School of Medicine</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <results_first_submitted>January 18, 2019</results_first_submitted>
  <results_first_submitted_qc>February 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 19, 2019</results_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02808338/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A multi-site study that accrued over 2016 and into the middle of 2017.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Screening</title>
          <description>All participants that consented to the study were considered for the participant flow. 15 participants were randomized to participate in the overnight in lab PSG's, these overnights were randomized to 1 of 4 interventions for each of the 4 overnights. This randomization scheme resulted in a large number of device sequences.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Overnight In-lab Polysomonography</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Philips BiPAP ASV</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ResMed S7 VPAP Adapt</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Philips BiPAP AutoSV Advanced System One</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ResMed S9 VPAP Adapt</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not given</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Take Home Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Five participants screened failed prior to collecting demographic information.</population>
      <group_list>
        <group group_id="B1">
          <title>Screening</title>
          <description>All participants that consented to the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.3" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Apnea Hypopnea Index Among Different Polysomnography Devices.</title>
        <description>The Apnea Hypopnea Index is the number of the apneas and hypopneas during one hour of sleep. The average of these events over one night were compared during each overnight device use.</description>
        <time_frame>4 nights</time_frame>
        <population>1 participant was excluded because he did not meet the criteria to receive ASV.</population>
        <group_list>
          <group group_id="O1">
            <title>Philips BiPAP AutoSV Advanced System One</title>
            <description>Philips Bilevel Postitive Airway Perssure (BiPAP) AutoSV Advanced System One: Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.</description>
          </group>
          <group group_id="O2">
            <title>Modified Philips BiPAP ASV</title>
            <description>Modified Philips BiPAP AutoServoventilation (ASV): This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.</description>
          </group>
          <group group_id="O3">
            <title>ResMed S7 VPAP Adapt</title>
            <description>ResMed S7 Variable Positive Airway Pressure (VPAP) Adapt: This device is FDA approved and will be set to predetermined setting.</description>
          </group>
          <group group_id="O4">
            <title>ResMed S9 VPAP Adapt</title>
            <description>ResMed S9 VPAP Adapt: This device is FDA approved and will be set to predetermined setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Apnea Hypopnea Index Among Different Polysomnography Devices.</title>
          <description>The Apnea Hypopnea Index is the number of the apneas and hypopneas during one hour of sleep. The average of these events over one night were compared during each overnight device use.</description>
          <population>1 participant was excluded because he did not meet the criteria to receive ASV.</population>
          <units>events per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="23.0"/>
                    <measurement group_id="O2" value="25.4" spread="25"/>
                    <measurement group_id="O3" value="24.1" spread="25.4"/>
                    <measurement group_id="O4" value="19.2" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>40 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Philips BiPAP AutoSV Advanced System One</title>
          <description>The Bi-Level Positive Airway Pressure system will be used and will be configured with these settings.
P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto
Philips BiPAP AutoSV Advanced System One: Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.</description>
        </group>
        <group group_id="E2">
          <title>Modified Philips BiPAP ASV</title>
          <description>The modified Philips BiPAP ASV will be configured with these settings P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto
Modified Philips BiPAP ASV: This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.</description>
        </group>
        <group group_id="E3">
          <title>ResMed S7 VPAP Adapt</title>
          <description>This is an FDA approved device and the following settings will be administered:
EEP: 4 PSmin: 3 PSMax: 16
ResMed S7 VPAP Adapt: This device is FDA approved and will be set to predetermined setting.</description>
        </group>
        <group group_id="E4">
          <title>ResMed S9 VPAP Adapt</title>
          <description>This is an FDA approved device and the following settings will be administered:
EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 20 Max Ramp: Off
ResMed S9 VPAP Adapt: This device is FDA approved and will be set to predetermined setting.</description>
        </group>
        <group group_id="E5">
          <title>Take Home - Modified Philips BiPAP ASV</title>
          <description>After the overnight PSGs participants took home the Modified Philips BiPAP ASV for 30 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>EKG abnormalities</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Paroxysmal Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>non-sustained ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>seziure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations Manager</name_or_title>
      <organization>Philips</organization>
      <phone>14125423669</phone>
      <email>jeremy.powers@philips.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

